Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with or without erythropoietin and G-CSF in low/intermediate-1 risk myelodysplastic syndrome
NL-OMON47453Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Lenalidomide alone with Lenalidomide with stepwise erythropoietin and G-CSF (2 arms). Primary endpoint: Hematological improvement. Started May 2009; status: active, not recruiting.
02
Drugs
lenalidomideepoetin betafilgrastim
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON47453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47453.